Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results

-- $7.0 million in third quarter LUMRYZ™ net revenue from U.S. commercial launch -- -- Generated robust demand for LUMRYZ with greater than 1,000 patients enrolled in RYZUPTM and more than 400 patients initiating therapy as of September 30 -- -- LUMRYZ to be added to preferred position for CVS commercial formularies effective January 1, 2024 -- -- Submitted sNDA for LUMRYZ in pediatric narcolepsy population on November 7th -- -- Management to host a conference call today at 8:30 a.m. ET -- DUBLI

Related Keywords

Ireland , Dublin , Courtney Turiano , Greg Divis , Lesley Stanley , Avadel Pharmaceuticals , Company Annual Report On Form , Drug Administration , Stern Investor Relations Inc , Nasdaq , Exchange Commission , Securities Exchange , Us Food Drug Administration , Chief Executive Officer , Recent Company , Supplemental New Drug Application , World Sleep , Third Quarter , Orphan Drug Exclusivity , Prescribing Information , Securities Act , Securities Exchange Act , Annual Report , Investor Relations , Months Ended September , Sodium Oxybate , Food And Drug Administration , Narcolepsy , Financial Results , The Company , Side Effects , Umryz ,